RGN-137: Completed Phase II enrollment

Sigma-Tau completed enrollment of 72 patients in a double-blind, placebo-controlled, dose-escalation, European Phase llb trial evaluating RGN-137 for up to 84 days. Sigma-Tau licensed European rights ...